Final 2-year analysis of a phase 3 RCT in 197 untreated patients with severe aplastic anaemia: adding eltrombopag to horse ATG plus cyclosporine raised complete response (62.4% vs 35.3%). 2-year overall survival of 91% vs 86% was not significantly different.
RCTn = 197
Risitano et al. Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study